Skip to Content


In the US, Peginesatide (peginesatide systemic) is a member of the drug class recombinant human erythropoietins and is used to treat Anemia Associated with Chronic Renal Failure.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Therapeutic Category

Antianemic agent

Chemical Name

Pegylated erytropoietin receptor agonist,N⁶.²¹,N⁶.²¹'-{[(N²,N⁶-bis{[ω-metoxypoly(oxyetylene)]carbonyl}-DL-lysyl-β-alanyl)imino]bis(metylenecarbonyl)}bis[acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-metionylglycyl-L-prolyl-L-isol (WHO)

Foreign Names

  • Peginesatidum (Latin)
  • Peginesatid (German)
  • Péginésatide (French)
  • Peginesatida (Spanish)

Generic Names

  • Peginesatide (OS: USAN)
  • AF37702 (IS)
  • Hematide (IS)
  • UNII-JX56W9N61Q (IS)

Brand Name

  • Omontys
    Takeda Pharmaceuticals U.S.A, United States


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.